Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $12.0 million.

  • Caribou Biosciences' Long-Term Investments fell 7737.76% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 7737.76%. This contributed to the annual value of $39.8 million for FY2024, which is 855.5% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Long-Term Investments is $12.0 million, which was down 7737.76% from $132000.0 recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Long-Term Investments ranged from a high of $69.4 million in Q4 2022 and a low of $132000.0 during Q2 2025
  • Its 5-year average for Long-Term Investments is $36.0 million, with a median of $38.8 million in 2021.
  • In the last 5 years, Caribou Biosciences' Long-Term Investments surged by 54543.67% in 2022 and then plummeted by 9973.67% in 2025.
  • Caribou Biosciences' Long-Term Investments (Quarter) stood at $37.7 million in 2021, then surged by 84.13% to $69.4 million in 2022, then tumbled by 37.18% to $43.6 million in 2023, then fell by 8.55% to $39.8 million in 2024, then crashed by 70.0% to $12.0 million in 2025.
  • Its Long-Term Investments was $12.0 million in Q3 2025, compared to $132000.0 in Q2 2025 and $9.3 million in Q1 2025.